Online Exclusives
Now You See It, Now You Don’t: RBCs in Glassfrogs
April 2023
JAK2 Inhibitor Receives Orphan Drug Designation
April 2023
Bispecific Antibody Approved for R/R FL
April 2023
Priority Review Granted to Glofitamab for R/R LBCL
April 2023
Editor's Corner
Battling Burnout
March 2023
Matthew Matasar, MD
Dr. Matthew Matasar discusses the challenges of burnout in the field of hematology and proposes solutions to lessen its occurrence.
Advertisement
Most Read Articles
Advertisement
Pulling Back the Curtain: Sarah O’Brien, MD
March 2023
In this edition, Sarah O’Brien, MD, discusses why she chose the subspeciality of pediatric hematology, some of her passion projects, and the meaning of work-life integration. Dr. O’Brien is a pediatric hematologist at Nationwide Children’s Hospital, the Abigail Wexner investigator in the Center for Child Health Equity and Outcomes Research at Nationwide Children’s Research Institute, and associate professor of pediatrics at The Ohio State University College of Medicine.
Which Modality Is Preferred in Hemophilia: Factor or Non-Factor Prophylaxis?
March 2023
In this edition of “Drawing First Blood,” Beth Warren, MD, and Alice Ma, MD, discuss the differences between factor and non-factor prophylaxis.
Glofitamab Shows Durable Remissions in R/R DLBCL
March 2023
A phase II trial included 155 patients with DLBCL who had either relapsed after or been refractory to at least two previous therapies. Patients were given glofitamab at a starting dose of 2.5 mg on the first day of the first 21-day cycle, slowly increasing to the target dose over multiple cycles.